Kategorie: Genitourinární nádory
Téma: Poster session II: Genitourinary malignancies - Renal cancer
Číslo abstraktu: P-7126
Methods: Nephrectomised pts with clear cell mRCC, KPS of ≥70%, no CNS metastases and adequate organ function received IFN (×3/week at a recommended dose of 9 MIU for up to 1 year) plus BEV (10 mg/kg q2w) or placebo until PD. Use of subsequent therapies was recorded and OS calculated in these subgroups.
Results: Between 06/04 and 10/05, 649 pts (641 treated) were randomised to BEV + IFN (n = 327) or IFN + placebo (n = 322). Post-protocol therapy was received by 180 (55%) pts in the BEV + IFN and 202 (63%) in the IFN + placebo arm; the majority (148 and 171) received 1 or 2 subsequent therapies. Pt characteristics, including MSKCC score, were similar in pts who received subsequent therapy and the overall population. The results of sequencing with different post-protocol therapies are shown below.
Conclusions: Although the AVOREN trial was not designed to examine the effect of 2nd-line therapy on OS, this retrospective exploratory analysis suggests a potential improvement in OS (greater than 30 months) in pts who receive BEV + IFN followed by subsequent therapies such as TKIs. The overall sequence of therapies should be considered when selecting 1st-line therapy for pts with mRCC, but prospective studies are required to confirm these findings.
Trial sponsored by F. Hoffmann-La Roche, Ltd.
Publikováno v: European Journal of Cancer Supplements, Vol 7 No 2, September 2009, Page 431
Datum přednesení příspěvku: 21. 9. 2009